Big Pharma-backed antifibrotic startup Blade has triggered the remaining tranche of last summer’s $45 million series B after placing its bets on a leading…

Startup Vir Biotechnology, guided by former Biogen CEO George Scangos, is unveiling a multifaceted pipeline of treatments for infectious diseases.

Johnson & Johnson had painted sirukumab and talacotuzumab as future blockbusters that would drive growth for years. Today, J&J abandoned those plans.

Drug accelerator Cydan has gained a $34 million injection as it eyes deeper inroads into rare diseases for its second fund.

Sanofi veteran Christopher Winter has been appointed as the new chief of R&D at drug discovery biotech Silicon.

The MET-TKI triggered partial responses in a significant minority of NSCLC patients who had progressed after treatment with an EGFR-TKI.

AstraZeneca admitted that some early data for Acerta's BTK inhibitor acalabrutinib was crooked.

The ALK inhibitor triggered responses in a significant minority of heavily pretreated patients, suggesting it can play a role in NSCLC treatment.

The antisense drug triggered a 20-point improvement against a score of neuropathy impairment, laying a marker for the upcoming showdown with Alnylam.

Roche will pay up to $387 million to license certain classes from the more than 100 groups of possibly novel antibiotics Warp Drive is analyzing.